Hepatocellular carcinoma
Conditions
Interventions
Group B:Conventional therapy after liver transplantation+ first therapy of intravenous injection with Licartin at the first weekend, the third weekend, sixth weekend of post-liver transplantation, tot
Group D:Control group: conventional therapy after liver transplantation and receive placebo at the time of therapy.
Group C:Injection of ADV-TK into peritoneum tissues around the liver during the liver transplantation operation and at week 3 and week 5 of post-operation.Intravenous injections of Licartin after each
Group A:Injection of ADV-TK into peritoneum tissues around the liver during the liver transplantation operation. The second and third injections of ADV-TK were administerted at week 3 and week 5 of po
Sponsors
Fourth Military Medical University
Eligibility
Sex/Gender
Male
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients are entirely voluntary, good compliance, sign the informed consent form; 2. Age between 18 to 70 years old; 3. Tumor size exceeds the Milan criteria, but without extra-liver organ metastasis and large blood vessel invasion; 4. Disgnosis of hepatocellular carcinoma after surgery by pathology; 5. Without surgical contraindication to liver transplant operation.
Exclusion criteria
Exclusion criteria: 1. Allergic reactions to adenovirus, Ganciclovir, or the same kinds of biological agents; 2. Allergic reactions to biological agents, hypersensitiveness; 3. Poor compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| No recurrence survival time or (and) No progress survival;Overall survival time;Recurrence rate;One-year survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Recurrence rate; | — |
Countries
China
Contacts
Public ContactZhi-Nan Chen
Outcome results
None listed